Beximco Pharmaceuticals Limited Stock

Equities

BXPHARMA

BD0453BXPH04

Pharmaceuticals

End-of-day quote Dhaka S.E. 06:00:00 2024-05-01 pm EDT 5-day change 1st Jan Change
118.4 BDT -0.50% Intraday chart for Beximco Pharmaceuticals Limited +1.98% -19.02%
Sales 2024 * 44.55B 409M Sales 2025 * 50.49B 464M Capitalization 52.82B 485M
Net income 2024 * 5.13B 47.14M Net income 2025 * 6B 55.12M EV / Sales 2024 * 1.32 x
Net Debt 2024 * 5.99B 55.05M Net Debt 2025 * 884M 8.12M EV / Sales 2025 * 1.06 x
P/E ratio 2024 *
9.63 x
P/E ratio 2025 *
7.84 x
Employees 5,700
Yield 2024 *
3.38%
Yield 2025 *
4.22%
Free-Float 76.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.50%
1 week+1.98%
Current month-0.50%
1 month+1.11%
3 months-10.30%
6 months-19.02%
Current year-19.02%
More quotes
1 week
116.20
Extreme 116.2
121.20
1 month
113.20
Extreme 113.2
121.20
Current year
110.00
Extreme 110
146.20
1 year
110.00
Extreme 110
146.20
3 years
110.00
Extreme 110
255.40
5 years
47.36
Extreme 47.3636
255.40
10 years
30.59
Extreme 30.5916
255.40
More quotes
Managers TitleAgeSince
Director of Finance/CFO 61 89-12-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder - 75-12-31
Founder - 75-12-31
Chief Executive Officer - 84-12-31
More insiders
Date Price Change Volume
24-05-02 118.4 -0.50% 105,753
24-04-30 119 +2.06% 123,704
24-04-29 116.6 -2.59% 74,645
24-04-28 119.7 +3.10% 108,792

End-of-day quote Dhaka S.E., May 01, 2024

More quotes
Beximco Pharmaceuticals Ltd. is a manufacturer and exporter of medicines in Bangladesh. The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a range of therapeutic categories. It offers products in different dosage forms including solid, liquid, cream and ointment, suppositories, metered dose inhaler, dry powder inhaler, nasal spray, sterile, lyophilized injectable and large volume intravenous fluids. It also manufactures active pharmaceutical ingredients (APIs) and renders contract manufacturing services to other companies. It produces different presentations, and the portfolio encompasses all key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal and others. The Company's products include Atrizin, Nomos, Azithrocin, Ceftoril, Bemsivir, Viraflu, Viracin, Rilovir, Flurium, Nervalin, Seropam, Nightus, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
118.4 BDT
Average target price
153.5 BDT
Spread / Average Target
+29.65%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BXPHARMA Stock